6-(二甲胺基)-3-氰基吡啶 | 154924-17-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(二甲胺基)-3-氰基吡啶
• 中文别名: 6-(二甲基氨基)-3-吡啶甲腈
• 英文名称: 6-(dimethylamino)nicotinonitrile
• 英文别名: 6-(dimethylamino)pyridine-3-carbonitrile
• CAS: 154924-17-1
• 化学式: C₈H₉N₃
• mdl: MFCD08272099
• 分子量: 147.18
• InChiKey: YIZXYFJKSCABES-UHFFFAOYSA-N

物化性质

• 熔点：
  66-68
• 沸点：
  330.9±22.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi

反应信息

• 作为反应物：
  描述：

  6-(二甲胺基)-3-氰基吡啶 在 吡啶 、 hydroxylamine-O-sulfonic acid 作用下， 以 甲醇 为溶剂， 生成 [1,2,4]噻唑并[1,5-a]吡啶-6-甲腈
  参考文献：
  名称：

  Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

  摘要：

  HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

  DOI：

  10.1021/jm500510f
• 作为产物：
  描述：

  2-氨基-5-氰基吡啶 、 N,N-二甲基甲酰胺二甲基缩醛 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-(二甲胺基)-3-氰基吡啶
  参考文献：
  名称：

  Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

  摘要：

  HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

  DOI：

  10.1021/jm500510f

文献信息

• [EN] NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS NMDA ET UTILISATIONS DE CEUX-CI
  申请人：CADENT THERAPEUTICS

  公开号：WO2018119374A1

  公开（公告）日：2018-06-28

  Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

  本文披露了部分杂芳化合物及其在治疗神经精神障碍，例如精神分裂症和重度抑郁症中的用途方法。提供了药物组合物和制备杂芳化合物的方法。这些化合物被认为可以调节NMDA受体。
• Transnitrilation from Dimethylmalononitrile to Aryl Grignard and Lithium Reagents: A Practical Method for Aryl Nitrile Synthesis
  作者：Jonathan T. Reeves、Christian A. Malapit、Frederic G. Buono、Kanwar P. Sidhu、Maurice A. Marsini、C. Avery Sader、Keith R. Fandrick、Carl A. Busacca、Chris H. Senanayake

  DOI：10.1021/jacs.5b06136

  日期：2015.7.29

  An electrophilic cyanation of aryl Grignard or lithium reagents, generated in situ from the corresponding aryl bromides or iodides, by a transnitrilation with dimethylmalononitrile (DMMN) was developed. DMMN is a commercially available, bench-stable solid. The transnitrilation with DMMN avoids the use of toxic reagents and transition metals and occurs under mild reaction conditions, even for extremely

  开发了芳基格氏试剂或锂试剂的亲电氰化，由相应的芳基溴化物或碘化物原位生成，通过与二甲基丙二腈 (DMMN) 进行腈基转移。DMMN 是市售的、工作台稳定的固体。使用 DMMN 进行的腈基转移避免了使用有毒试剂和过渡金属，并且在温和的反应条件下发生，即使对于空间位阻非常大的底物也是如此。由定向邻位锂化产生的芳基锂物质的腈基转腈作用使净 CH 氰化成为可能。Thorpe 型亚胺加合物在反应中的中介作用是通过从淬灭反应中分离相应的酮来支持的。计算研究支持亚胺加合物逆向索普碎裂的能量有利性。
• [EN] 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF<br/>[FR] COMPOSÉS DE 2-ARYL- ET DE 2-HÉTÉROARYL-THIAZOLYLE, LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：WYETH CORP

  公开号：WO2009120826A1

  公开（公告）日：2009-10-01

  The present invention discloses fused bicyclic 2-aryl- or 2-heteroarylthiazolyl compounds and their pharmaceutically acceptable salts and esters thereof, which are useful for inhibiting the growth of cancerous cells, inhibiting human breast carcinoma tumor growth in particular and to treat diseases or disorders associated with securin, including elevated securin levels.

  本发明揭示了融合的双环2-芳基或2-杂环芳基噻唑基化合物及其药用盐和酯，这些化合物对抑制癌细胞的生长、特别是抑制人类乳腺癌肿瘤的生长以及治疗与分泌蛋白相关的疾病或紊乱，包括高水平的分泌蛋白水平具有用处。
• Expanding Synthesizable Space of Disubstituted 1,2,4-Oxadiazoles
  作者：Andrey Tolmachev、Andrey V. Bogolubsky、Sergey E. Pipko、Alexander V. Grishchenko、Dmytro V. Ushakov、Anton V. Zhemera、Oleksandr O. Viniychuk、Anzhelika I. Konovets、Olga A. Zaporozhets、Pavel K. Mykhailiuk、Yurii S. Moroz

  DOI：10.1021/acscombsci.6b00103

  日期：2016.10.10

  One-pot synthesis of 3,5-disubstituted 1,2,4-oxadiazoles from carboxylic acids and nitriles was optimized to parallel chemistry. The method was validated on a 141 member library; the desired products were recovered with a high success rate and in moderate yields. Practical application of the approach was demonstrated in the synthesis of bioactive compound pifexole and agonists of free fatty acid receptor

  优化了从羧酸和腈的一锅法合成3,5-二取代的1,2,4-恶二唑的平行化学反应。该方法已在141个成员库中得到验证；以高成功率和中等收率回收了所需的产品。该方法在生物活性化合物吡非索和游离脂肪酸受体1激动剂的合成中得到了实际应用。在此基础上，列举了4 948 100种可合成的药物样3,5-二取代1,2,4-恶二唑类化合物。方法和可用的经过验证的试剂。
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS<br/>[FR] COMPOSES HETEROCYCLIQUES UTILES EN TANT QU'ACTIVATEURS DE NURR-1
  申请人：NOVARTIS AG

  公开号：WO2004072050A1

  公开（公告）日：2004-08-26

  The present invention relates to compounds of formula (I) : wherein R1 is hydroxy, C1-4 alkoxy ,amino, C1-4 alkyl-amino, di C1-4 alkylamino , benzyloxy or C2-C7 alkanoyl, R2 is C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4 alkoxy, CF3, halogen, C1-4alkylamino, di C1-4alkylamino, di C1-4 alkylamino C1-4 alkoxy or N-C1-4 alkoxy C1-4 alkyl-N­-C1-4 alkylamino, N-C1-4 alkyl-piperazinyl, morpholinyl or pyrrolidinyl-C1-4 alkoxy, wherein the C1-4 alkyl radicals in R2 are optionally further substituted by C1-4 alkyl, halogen, cyano, amino, alkoxy or alkylthio, X is N or O, Y is N, O or CH, Z is N or CH, and W is N or CH, provided that (a) R1 is not hydroxy or C1-4 alkoxy when R2 is CF3, X is O, Y is CH, Z is N and W is CH, (b) R1 is not hydroxy or C1-4 alkoxy when R2 is CF3 or chloro, X is N, Y is O, Z is CH and W is CH, (c) R1 is not hydroxy when R2 is CF3, X is O, Y is N, Z is CH and W is CH and (d) X and Y are not simultaneously O, the salts thereof; their preparation, their use and pharmaceutical compositions containing them.

  本发明涉及以下化合物的公式（I）：其中R1是羟基，C1-4烷氧基，氨基，C1-4烷基氨基，二甲基胺基，苄氧基或C2-C7烷酰基，R2是C1-4烷基，C1-4烷氧基，C1-4烷氧基C1-4烷氧基，CF3，卤素，C1-4烷基氨基，二C1-4烷基胺基，二C1-4烷基胺基C1-4烷氧基或N-C1-4烷氧基C1-4烷基-N-C1-4烷基胺基，N-C1-4烷基哌嗪基，吗啉基或吡咯啉基-C1-4烷氧基，其中R2中的C1-4烷基基团可以进一步被C1-4烷基，卤素，氰基，氨基，烷氧基或烷基硫基取代，X是N或O，Y是N，O或CH，Z是N或CH，W是N或CH，但前提是（a）当R2是CF3，X是O，Y是CH，Z是N，W是CH时，R1不是羟基或C1-4烷氧基，（b）当R2是CF3或氯时，X是N，Y是O，Z是CH，W是CH时，R1不是羟基或C1-4烷氧基，（c）当R2是CF3，X是O，Y是N，Z是CH，W是CH时，R1不是羟基，（d）X和Y不同时是O，以及它们的盐；它们的制备，其用途以及含有它们的药物组合物。